The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691).

@article{Fidock2011TheII,
  title={The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691).},
  author={Mark D Fidock and Bernard E. Souberbielle and Christy Laxton and Jakirty Rawal and Oona E Delpuech-Adams and Timothy P. Corey and PeterG. Colman and Vinay Kumar and John B. Cheng and Katie E. Wright and Sivagami Srinivasan and Kannagi Rana and Ceh Craig and Nigel Horscroft and Manos Perros and Michael Westby and Rob Webster and Elna van der Ryst},
  journal={Clinical pharmacology and therapeutics},
  year={2011},
  volume={89 6},
  pages={
          821-9
        }
}
Hepatitis C virus (HCV) infection is an issue of global concern, and studies are ongoing to identify new therapies that are both effective and safe. PF-4878691 is a Toll-like receptor 7 (TLR7) agonist modeled so as to dissociate its antiviral activities from its inflammatory activities. In a proof-of-mechanism study in healthy volunteers who received doses of 3, 6, and 9 mg of PF-4878691 twice a week for 2 weeks, PF-4878691 induced biomarkers of the immune and interferon (IFN) responses in a… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 32 CITATIONS

Similar Papers

Loading similar papers…